Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with (177)Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCR...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:EJNMMI Res
Main Authors: Groener, Daniel, Nguyen, Cam Tu, Baumgarten, Justus, Bockisch, Benjamin, Davis, Karen, Happel, Christian, Mader, Nicolai, Nguyen Ngoc, Christina, Wichert, Jennifer, Banek, Severine, Mandel, Philipp, Chun, Felix K. H., Tselis, Nikolaos, Grünwald, Frank, Sabet, Amir
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2021
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8254689/
https://ncbi.nlm.nih.gov/pubmed/34216290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-021-00805-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares